Abstract:BACKGROUND:PRDM (PRDI-BF1 and RIZ domain containing) proteins are zinc finger proteins involved in multiple cellular regulations by acting as epigenetic modifiers. We studied a recently identified PRDM member PRDM5 for its epigenetic abnormality and tumor suppressive functions in multiple tumorigeneses.METHODOLOGY/PRINCIPAL FINDINGS:Semi-quantitative RT-PCR showed that PRDM5 was broadly expressed in human normal tissues, but frequently silenced or downregulated in multiple carcinoma cell lines due to promoter CpG methylation, including 80% (4/5) nasopharyngeal, 44% (8/18) esophageal, 76% (13/17) gastric, 50% (2/4) cervical, and 25% (3/12) hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell lines. PRDM5 expression could be restored by 5-aza-2'-deoxycytidine demethylation treatment in silenced cell lines. PRDM5 methylation was frequently detected by methylation-specific PCR (MSP) in multiple primary tumors, including 93% (43/46) nasopharyngeal, 58% (25/43) esophageal, 88% (37/42) gastric and 63% (29/46) hepatocellular tumors. PRDM5 was further found a stress-responsive gene, but its response was impaired when the promoter was methylated. Ectopic PRDM5 expression significantly inhibited tumor cell clonogenicity, accompanied by the inhibition of TCF/β-catenin-dependent transcription and downregulation of CDK4, TWIST1 and MDM2 oncogenes, while knocking down of PRDM5 expression lead to increased cell proliferation. ChIP assay showed that PRDM5 bound to its target gene promoters and suppressed their transcription. An inverse correlation between the expression of PRDM5 and activated β-catenin was also observed in cell lines.CONCLUSIONS/SIGNIFICANCE:PRDM5 functions as a tumor suppressor at least partially through antagonizing aberrant WNT/β-catenin signaling and oncogene expression. Frequent epigenetic silencing of PRDM5 is involved in multiple tumorigeneses, which could serve as a tumor biomarker.

Sirtuin 7–mediated Deacetylation of WD Repeat Domain 77 (WDR77) Suppresses Cancer Cell Growth by Reducing WDR77/PRMT5 Transmethylase Complex Activity

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

SIRT7 Is an RNA-Activated Protein Lysine Deacylase.

SIRT7 sustains tumor development and radioresistance by repressing endoplasmic reticulum stress-induced apoptosis in cutaneous melanoma

SIRT1 deacetylates WEE1 and sensitizes cancer cells to WEE1 inhibition

Depletion of the Proteasome Subunit Psma7 Inhibits Colorectal Cancer Cell Tumorigenicity and Migration

SIRT7 is a Histone Desuccinylase That Functionally Links to Chromatin Compaction and Genome Stability

Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1)

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours

O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REGγ interaction

WDR79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated regulation of the Mdm2-p53 pathway

An NAD+-Dependent Deacetylase SIRT7 Promotes HCC Development Through Deacetylation of USP39

Sirt7 Deacetylates Strap To Regulate P53 Activity And Stability

SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes.

Regulation of Wrn Protein Cellular Localization and Enzymatic Activities by Sirt1-Mediated Deacetylation

Deacetylation of Serine Hydroxymethyl-Transferase 2 by SIRT3 Promotes Colorectal Carcinogenesis

A Click Chemistry Approach Reveals the Chromatin-Dependent Histone H3K36 Deacylase Nature of SIRT7.

The Current Progress of Histone Deacetylase SIRT7

SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells.

Mammalian SIRT6 Represses Invasive Cancer Cell Phenotypes through ATP Citrate Lyase (ACLY)-Dependent Histone Acetylation